Truist Securities Raises RVMD Price Target to $241
Key Points
- Truist Securities maintained a Buy rating on Revolution Medicines, Inc. and adjusted its price target from $240 to $241 on October 19, 2026.
- Truist Securities's $241 price target implies 33.11% upside from Revolution Medicines, Inc.'s ($RVMD) current $181.06 share price.
- The clinical-stage oncology firm has an upcoming earnings report scheduled for November 4, 2026, amid an active pipeline of targeted RAS-addicted cancer therapies.
- Institutional investors and company insiders have seen heavy portfolio adjustments, while Wall Street consensus leans toward a strong buy recommendation.
Get Revolution Medicines text alerts
We text you when insiders, Congress, analysts or big funds move on $RVMD.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Revolution Medicines, Inc. alert may contain errors. Disclosures
On October 19, 2026, Truist Securities maintained its Buy rating on Revolution Medicines, Inc. (NASDAQ: RVMD) and nudged its price target from $240 to $241. The research note was issued as the biotechnology company traded right near its closing level of $181.01 on October 19, 2026.
RVMD
Revolution Medicines, Inc.
Truist Securities vs. the S&P 500
Hypothetical returns from Truist Securities's disclosed trades, not real profit or advice. How we model this.
Truist Securities' Call on Revolution Medicines
Truist Securities kept its positive stance on the precision oncology developer, lifting the target price slightly to $241. Analysts across Wall Street continue to weigh in on the clinical-stage pipeline as the company develops targeted therapies for RAS-addicted cancers.
Other Institutional Activity in Revolution Medicines
Large financial institutions have been actively shifting their holdings in the biotechnology firm. Farallon Capital Management LLC trimmed its stake by 54,421 shares, ending with 13,550,796 shares worth about $2,452,829,509. Baker Bros. Advisors, LP grew its holdings by 1,888,116 shares, ending with 11,443,357 shares worth about $2,071,361,987. Jupiter Topco LLC boosted its holdings by 5,368,072 shares, ending with 10,736,145 shares worth about $1,943,349,547. Darwin Global Management, Ltd. increased its holdings by 8,418,823 shares, ending with 10,629,822 shares worth about $1,924,104,021. Nextech Invest, Ltd. kept its position steady with 7,601,087 shares valued at about $1,375,872,716.
Revolution Medicines, Inc. Stock Down 4.3%
Shares recently changed hands around $181.06, sitting below the 50-day moving average and about 19.4% above the 200-day moving average as of October 19, 2026. The stock closed at $181.01 on October 19, 2026.
$RVMD price target
Revolution Medicines, Inc. daily closes and this analyst's $241 target. Not advice.
Recent Earnings
Revolution Medicines operates as a clinical-stage precision oncology company with 883 employees based in Redwood City, California. The firm does not currently have positive trailing-twelve-month earnings, posting a negative earnings per share of $8.87 and a return on equity of -79.1%. Investors are awaiting the next corporate updates when the company reports earnings on November 4, 2026.
Insider Buying and Selling at Revolution Medicines, Inc.
Company insiders have executed multiple transactions in recent weeks. Director Elizabeth M. Anderson disposed of 10,143 shares valued at $1,958,016 on September 22, 2026. Officer Anthony Mancini parted with 3,708 shares worth $743,285 on September 25, 2026. General Counsel Jeffrey Todd Cislini sold 765 shares at $207.32 per share for a total of $158,600 on September 25, 2026. Officer Alan B. Sandler disposed of 6,309 shares worth $1,275,294 on September 29, 2026.
Analysts Set New Price Targets
Wall Street firms have kept a broadly positive outlook on the stock. RBC Capital maintained an Outperform rating with a $259 target on October 8, 2026, and later moved the target to $260 on October 14, 2026. Needham reiterated a Buy rating with a $275 target on October 15, 2026. William Blair initiated coverage with an Outperform rating on October 16, 2026. Overall, the stock carries a strong buy consensus rating from 24 analyst opinions, with a mean target price of $257.80.
About Revolution Medicines
Revolution Medicines is a clinical-stage biotechnology company that builds targeted therapies for difficult cancers. Its scientific pipeline focuses on RAS(ON) inhibitors and companion inhibitors designed to halt cancer cell survival pathways. This research underpins the interest from institutional investors and Wall Street analysts alike.
Bottom Line
Investors will keep an eye on the upcoming earnings report scheduled for November 4, 2026, to gauge progress in the clinical pipeline. Truist Securities' updated target reflects continued confidence in the oncology developer's research direction.
Related Filing Alerts
Source: Truist Securities's rating change on $RVMD (Oct 19, 2026). Written by software, not financial advice. How we make alerts